GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

[1]  Rameen Beroukhim,et al.  Sound credit scores and financial decisions despite cognitive aging , 2014, Proceedings of the National Academy of Sciences.

[2]  B. Stack,et al.  BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. , 2014, Cancer research.

[3]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[4]  J. Qi,et al.  BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD , 2014, Molecular Cancer Therapeutics.

[5]  Paul Shinn,et al.  Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.

[6]  R. Beroukhim,et al.  Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition , 2014, Nature Medicine.

[7]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[8]  S. Hilsenbeck,et al.  An epigenomic approach to therapy for tamoxifen-resistant breast cancer , 2014, Cell Research.

[9]  D. Bentrem,et al.  Cancer Biology and Signal Transduction Bet Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-dimensional Collagen , 2022 .

[10]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[11]  J. Qi,et al.  Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 , 2014, Molecular Cancer Therapeutics.

[12]  H. Uramoto,et al.  Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling. , 2013, Cancer research.

[13]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[14]  S. Dangi‐Garimella,et al.  Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression , 2013, PloS one.

[15]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[16]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[17]  Carla M. T. Bauer,et al.  BET Bromodomain Proteins Mediate Downstream Signaling Events following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosis , 2013, Molecular Pharmacology.

[18]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[19]  E. Reed,et al.  Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair , 2012, Oncogene.

[20]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[21]  Zachary C. Dobbin,et al.  Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer , 2012, Molecular Cancer Therapeutics.

[22]  J. Licht,et al.  Emerging epigenetic targets and therapies in cancer medicine. , 2012, Cancer discovery.

[23]  S. Dangi‐Garimella,et al.  Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. , 2012, The Journal of surgical research.

[24]  S. Dangi‐Garimella,et al.  Interplay between β1-Integrin and Rho Signaling Regulates Differential Scattering and Motility of Pancreatic Cancer Cells by Snail and Slug Proteins* , 2012, The Journal of Biological Chemistry.

[25]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[26]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[27]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[28]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[29]  S. Dangi‐Garimella,et al.  Pancreatic Cancer Cells Respond to Type I Collagen by Inducing Snail Expression to Promote Membrane Type 1 Matrix Metalloproteinase-dependent Collagen Invasion* , 2011, The Journal of Biological Chemistry.

[30]  S. Dangi‐Garimella,et al.  Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. , 2011, Cancer research.

[31]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[32]  A. Redig,et al.  Rho-ROCK-Myosin Signaling Meditates Membrane Type 1 Matrix Metalloproteinase-induced Cellular Aggregation of Keratinocytes* , 2010, The Journal of Biological Chemistry.

[33]  M. Hemler,et al.  Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. , 2010, Cancer Research.

[34]  Liang Zhiyong,et al.  Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines , 2009, Molecular Cancer.

[35]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[36]  F. Verrecchia,et al.  Cloning of the Human GLI2 Promoter , 2009, The Journal of Biological Chemistry.

[37]  H. Zhang,et al.  MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. , 2009, Genes & development.

[38]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[39]  J. Hescheler,et al.  The High Mobility Group Protein HMGA2: A Co-Regulator of Chromatin Structure and Pluripotency in Stem Cells? , 2009, Stem Cell Reviews and Reports.

[40]  Zhiwei Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.

[41]  W. Simonds,et al.  The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene , 2008, Proceedings of the National Academy of Sciences.

[42]  M. Gleave,et al.  GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[43]  M. Wernli,et al.  Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis , 2008, Oncogene.

[44]  A. Fusco,et al.  Roles of HMGA proteins in cancer , 2007, Nature Reviews Cancer.

[45]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[46]  B. Monia,et al.  Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. , 2007, Cancer research.

[47]  D. Klimstra,et al.  Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis , 2007, Proceedings of the National Academy of Sciences.

[48]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[49]  J. Haley,et al.  Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition , 2007, Molecular Cancer Therapeutics.

[50]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[51]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[52]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A , 2005 .

[53]  M. Kasper,et al.  Activation of the BCL2 Promoter in Response to Hedgehog/GLI Signal Transduction Is Predominantly Mediated by GLI2 , 2004, Cancer Research.

[54]  Gregory Y. Lauwers,et al.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.

[55]  F. Aoudjit,et al.  Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells , 2001, Oncogene.

[56]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[57]  R. Prinjha,et al.  Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. , 2014, Blood.